
==== Front
Radiol Bras
Radiol Bras
rb
Radiologia Brasileira
0100-3984
1678-7099
Publicação do Colégio Brasileiro de Radiologia e Diagnóstico por Imagem

00104
10.1590/0100-3984.2024.57.e5-en
Editorial
The importance of PSMA PET/CT in evaluating biochemical recurrence in patients with prostate cancer and the need to expand access to this examination via public health care systems
http://orcid.org/0000-0001-8762-0875
Baroni Ronaldo Hueb 1*
1 Hospital Israelita Albert Einstein, Faculdade Israelita de Ciências da Saúde Albert Einstein, Colégio Brasileiro de Radiologia e Diagnóstico por Imagem. São Paulo, SP, Brazil. Email: rhbaroni@gmail.com
23 9 2024
Jan-Dec 2024
57 e5https://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
==== Body
pmcProstate cancer is a highly prevalent neoplasm, with an estimated 288,300 and 71,730 new cases occurring in the United States and Brazil, respectively, in 2023(1,2). That high prevalence results in high health costs for the population, whether in the diagnosis, treatment, or follow-up of the affected patients. In recent decades, great progress has been made toward promoting the diagnosis of prostate cancer in its earlier stages (thus reducing morbidity and mortality). For example, the use of prostate-specific antigen (PSA) testing has become widespread, as has, more recently, multiparametric magnetic resonance imaging to stratify the risk of clinically significant neoplasms and to guide biopsies(3). Nevertheless, up to 40% of patients undergoing radical prostatectomy and up to 50% of patients undergoing radiotherapy will develop biochemical recurrence within the first 10 years after the treatment(4-6).

The advent of gallium-68-prostate-specific membrane antigen positron emission tomography/computed tomography (68Ga-PSMA PET/CT), in the early 2010s, represented a true paradigm shift in the evaluation of biochemical recurrence after prostate cancer treatment. Since then, hundreds of studies have been carried out, initially experimental and retrospective, followed by prospective studies, mainly in centers in Europe and subsequently in other countries around the world, including Brazil(7). In 2015, the largest prospective series ever published showed that 68Ga-PSMA PET/CT had a sensitivity of 76.6%, specificity of 100%, positive predictive value of 91.4%, and negative predictive value of 100% for the evaluation of lesions in patients with biochemical recurrence(8). In 2016, a systematic review and meta-analysis demonstrated that 68Ga-PSMA PET/CT positivity increased in parallel with increasing serum PSA levels in cases of biochemical recurrence, reaching 95% positivity in patients with a PSA > 2 ng/mL(9). Despite these extremely impressive results, it took a long time for PSMA PET/CT to gain approval and wider clinical use in several countries, mainly in public health care systems, because of the cost of producing the radiopharmaceutical and the limited availability of PET equipment, among other factors.

The work conducted by Bogoni et al.(10), recently published in Radiologia Brasileira, highlights an important aspect related to the use of PSMA PET/CT in public health care facilities in Brazil. Although the authors found that the use of the examination in patients with biochemical recurrence has resulted in an increase in the cost per patient in comparison with the standard investigation strategy (without the use of PSMA PET/CT), they also noted a change in the treatment strategy in a substantial proportion (61%) of the patients, with a reduction in the number of futile/inappropriate salvage therapies. That could reduce the overall cost of treating such patients and enable better allocation of resources (for example, to PSMA PET/CT itself).

Cost-effectiveness studies regarding PSMA PET/CT are still scarce because of the short time that the radiopharmaceutical has been in clinical use. The cost-effectiveness of PSMA PET/CT in the primary staging of prostate cancer has already been evaluated in a few studies, the main one being a multicenter, prospective, randomized study(11), in which PSMA PET/CT was shown to have comparatively lower direct costs, as well as greater accuracy, in relation to conventional diagnostic methods (computed tomography and bone scintigraphy).

We hope that studies like those cited above will become increasingly more common. Such studies will enable better allocation of resources and the development of guidelines for access to supplies and diagnostic tests via public health care systems that are more appropriate, especially in lowto middle-income countries like Brazil.

Professor at the Faculdade Israelita de Ciências da Saúde Albert Einstein, São Paulo, SP, Brazil, Medical Manager of the Imaging Sector at Hospital Israelita Albert Einstein, São Paulo, SP, Brazil, Scientific Director of the Colégio Brasileiro de Radiologia e Diagnóstico por Imagem.
==== Refs
REFERENCES

1 Siegel RL Miller KD Wagle NS Cancer statistics, 2023 CA Cancer J Clin 2023 73 17 48 36633525
2 Instituto Nacional de Câncer Estimativa 2023: incidência de câncer no Brasil Rio de Janeiro Instituto Nacional de Câncer; 2022 cited 2022 May 10 Available from: https://www.inca.gov.br/publicacoes/livros/estimativa-2023-incidencia-de-cancer-no-brasil
3 Stabile A Giganti F Rosenkrantz AB Multiparametric MRI for prostate cancer diagnosis: current status and future directions Nat Rev Urol 2020 17 41 61 31316185
4 Roehl KA Han M Ramos CG Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results J Urol 2004 172 910 914 15310996
5 Freedland SJ Humphreys EB Mangold LA Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 2005 294 433 439 16046649
6 Kupelian PA Mahadevan A Reddy CA Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer Urology 2006 68 593 598 16979731
7 Eiber M Maurer T Souvatzoglou M Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy J Nucl Med 2015 56 668 674 25791990
8 Afshar-Oromieh A Avtzi E Giesel FL The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer Eur J Nucl Med Mol Imaging 2015 42 197 209 25411132
9 Perera M Papa N Christidis D Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis Eur Urol 2016 70 926 937 27363387
10 Bogoni M Cerci JJ Trindade EM PSMA PET/CT in the Brazilian Unified Healthcare System reduces costs with futile salvage therapies in the management of cases of biochemical recurrence of prostate cancer Radiol Bras 2024 57 e20240024 39268043
11 Holzgreve A Unterrainer M Calais J Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial Eur J Nucl Med Mol Imaging 2023 50 3750 3754 37428216
